Lv4
770 积分 2024-09-14 加入
Mecanismos de resistencia en bacterias gramnegativas
11天前
已关闭
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
1个月前
已完结
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
1个月前
已完结
Prevention of colistin-induced neurotoxicity: a narrative review of preclinical data
1个月前
已完结
Recent advances and perspectives in the design and development of polymyxins
1个月前
已完结
Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206
1个月前
已完结
Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium
1个月前
已完结
Colistin plus meropenem versus colistin alone for invasive infections caused by carbapenem-resistant Acinetobacter baumannii: a rapid systematic review of randomized controlled trials using Bayesian meta-analysis
1个月前
已完结
β-lactam antibiotics: An overview from a medicinal chemistry perspective
1个月前
已完结
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
1个月前
已完结
皖公网安备34019202002308
